Who Are the Core Customers of Lannett Company Company?

The core customers are the Big Three pharmaceutical wholesalers-Cencora, Cardinal Health, and McKesson-which together handle roughly 90% of U.S. pharmaceutical distribution; these Lannett Company customers drive volume, payment terms, and shelf placement.

Retail pharmacy chains like CVS and Walgreens and Group Purchasing Organizations (GPOs) for hospitals and health systems form the next tier, purchasing through wholesalers or direct contracts and influencing formulary inclusion.

Lannett serves institutions and businesses-wholesalers, hospitals, health systems, and retail pharmacy procurement-so its market role is B2B and B2B2C rather than direct-to-consumer; institutional buyers prioritize supply reliability and regulatory compliance.

In 2025 and into 2026 the most commercially important segment is institutional buyers and wholesalers seeking complex generics-insulin glargine and respiratory injectables-where demand and margins depend on specialized manufacturing capacity and consistent lot supply; contract volumes to wholesalers remain the main revenue driver. Read more on recent commercial trends in Product Growth of Lannett Company Company.

Most demand comes from retail and independent pharmacies and pharmaceutical wholesalers across the United States because generics dominate prescription fills; this aligns with Lannett Company customers who buy high-volume, lower-cost alternatives after patent expiries.

Hospitals and healthcare systems, plus government and VA purchasers, create steady institutional demand for injectable and hospital-use generics; pharmaceutical wholesalers aggregate and route large contracts to these buyers.

Lannett's manufacturing footprint in states such as Indiana supports a Made in the USA advantage for institutional procurement; revenue mix historically skews toward retail-channel sales and wholesale distribution, which drive the bulk of unit volumes.

As of early 2026, demand is intense in the complex generic space-especially insulin and biosimilar-adjacent therapies-where the U.S. total addressable market exceeds $20,000,000,000; this growth pulls interest from Lannett contract manufacturing clients and partners and from large drug wholesalers.

Lannett pursues complex generics and CMO work, using its existing plants to serve pharmaceutical wholesalers, hospitals and healthcare systems, and contract partners; this added service line lifted service revenue contribution in 2025 versus 2022 levels, according to company disclosures. The move brings in institutional buyers and international customers while keeping Lannett Company customers anchored to legacy oral solids.

Lannett retains retail and independent pharmacies and wholesalers by maintaining production of essential medicines at scale, ensuring stable supply to CVS/Walgreens-style purchasers and government and VA purchasers. Concentrated R&D on fewer, higher-value molecules in 2025 preserves product continuity for Lannett core customers and reduces price-erosion exposure.

Repeat demand comes from long-term contracts with distributors and hospitals plus CMO relationships; renewals and multi-year supply agreements increase stickiness for Lannett contract manufacturing clients and partners. Volume-driven purchases of legacy generics keep procurement departments and Lannett generic drug buyers returning for baseline SKUs.

The strongest growth lever is CMO and complex-generic launches, combined with focused R&D spend; by concentrating capital on high-barrier molecules, Lannett increases gross margins and targets biosimilar participation while preserving volume from legacy products. This dual-track approach supports relationships with Lannett customers hospitals pharmacies and wholesalers and attracts new institutional buyers.